Gilead Sciences' (GILD) Antiviral Drug Remdesivir Flops in First trial - FT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Gilead Sciences (GILD) China Trial Results 'In Line with our Expectations' - RBC
April 23, 2020 1:40 PM EDTRBC Capital analyst Brian Abrahams weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
"If this is ultimately confirmed, this would be completely in line with our... More
Gilead Sciences (GILD) Remdesivir China Results 'Very Sobering' - Baird
April 23, 2020 1:34 PM EDTBaird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
Skorney commented, "This afternoon, an abstract leaked indicating that Gilead's remdesivir failed to provide a benefit... More
Gilead Sciences (GILD) Halted on LUDP
April 23, 2020 12:46 PM EDTGilead Sciences (NASDAQ: GILD) Halted on LUDP
... More